Autoimmune-like syndromes during TNF blockade: Does infection have a role?

Nature Reviews Rheumatology

Volumn 7, Issue 7, 2011, Pages 429-434

  Prinz, Joerg C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; DOUBLE STRANDED DNA; DOXYCYCLINE; GLUCOCORTICOID; HERMES ANTIGEN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANTIBODY TITER; ARTHRITIS; ARTIFICIAL VENTILATION; ASCITES; AUTOIMMUNE DISEASE; AUTOIMMUNE LIKE SYNDROME; AUTOIMMUNITY; BELL PALSY; CASE REPORT; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE ASSOCIATION; FEMALE; FEVER; HUMAN; IMMUNOPATHOGENESIS; INTERSTITIAL PNEUMONIA; LUPUS LIKE SYNDROME; LYME DISEASE; MALAISE; MALE; NEUROPATHY; PERICARDITIS; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HUMANS; INFECTION; SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959932561     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.35     Document Type: Review

References (44)

1. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279 (2008).
2. Askling, J. & Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 138-144 (2008). (Pubitemid 351339884)
3. Ramos-Casals, M. et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun. Rev. 9, 188-193 (2009).
4. Galloway, J. B. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50, 124-131 (2011).
5. Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242-251 (2007). (Pubitemid 47067483)
6. Costa, M. F., Said, N. R. & Zimmermann, B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin. Arthritis Rheum. 37, 381-387 (2008). (Pubitemid 351734520)
7. De Bandt, M. et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7, R545-R551 (2005).
8. Aringer, M., Graninger, W. B., Steiner, G. & Smolen, J. S. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50, 3161-3169 (2004). (Pubitemid 39371992)
9. St?bgen, J. P. Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 37, 281-292 (2008).
10. Tristano, A. G. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J. Neurol. 257, 1421-1431 (2010).
11. Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006). (Pubitemid 44354221)
12. Gaipl, U. S. et al. Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9, 173-187 (2006).
13. Hart, S. P., Dougherty, G. J., Haslett, C. & Dransfield, I. CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J. Immunol. 159, 919-925 (1997). (Pubitemid 127484246)
14. Molin, S., Ruzicka, T. & Prinz, J. C. Borreliosis mimicking lupus-like syndrome during infliximab treatment. Clin. Exp. Dermatol. 35, 631-633 (2010).
15. Molin, S., Ruzicka, T. & Prinz, J. C. Bell's palsy during etanercept treatment caused by neuroborreliosis. Br. J. Dermatol. 163, 228-230 (2010).
16. Liebau, P. et al. Management of herpes simplex virus type 1 pneumonia following liver transplantation. Infection 24, 130-135 (1996). (Pubitemid 26137091)
17. Andreoletti, L., Leveque, N., Boulagnon, C., Brasselet, C. & Fornes, P. Viral causes of human myocarditis. Arch. Cardiovasc. Dis. 102, 559-568 (2009).
18. Atassi, M. Z. & Casali, P. Molecular mechanisms of autoimmunity. Autoimmunity 41, 123-132 (2008). (Pubitemid 351372294)
19. Krieg, A. M. & Vollmer, J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 220, 251-269 (2007). (Pubitemid 350045572)
20. Fujinami, R. S., von Herrath, M. G., Christen, U. & Whitton, J. L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 19, 80-94 (2006). (Pubitemid 43157648)
21. Brocke, S. et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365, 642-644 (1993). (Pubitemid 23350533)
22. Berlin, T. et al. Autoantibodies in nonautoimmune individuals during infections. Ann. NY Acad. Sci. 1108, 584-593 (2007). (Pubitemid 47528772)
23. Ramos-Casals, M. et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 87, 311-318 (2008).
24. Poole, B. D., Scofield, R. H., Harley, J. B. & James, J. A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39, 63-70 (2006). (Pubitemid 43878521)
25. Quan, T. E., Roman, R. M., Rudenga, B. J., Holers, V. M. & Craft, J. E. Epstein-Barr virus promotes interferon-α production by plasmacytoid dendritic cells. Arthritis Rheum. 62, 1693-1701 (2010).
26. Balandraud, N. et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 48, 1223-1228 (2003). (Pubitemid 36554521)
27. Domm, S., Cinatl, J. & Mrowietz, U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br. J. Dermatol. 159, 1217-1228 (2008).
28. van de Berg, P. J. et al. Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J. Infect. Dis. 202, 690-699 (2010).
29. Curtis, H. A., Singh, T. & Newkirk, M. M. Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1-70 kDa small nuclear ribonucleoprotein. Eur. J. Immunol. 29, 3643-3653 (1999). (Pubitemid 29527813)
30. Rekvig, O. P. et al. Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J. Clin. Invest. 99, 2045-2054 (1997). (Pubitemid 27175953)
31. Seve, P. et al. Lupus-like presentation of parvovirus B19 infection. Semin. Arthritis Rheum. 34, 642-648 (2005). (Pubitemid 40193362)
32. Gustafson, R., Svenungsson, B., Gardulf, A., Stiernstedt, G. & Forsgren, M. Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population. Scand. J. Infect. Dis. 22, 297-306 (1990).
33. Witt, M. N., Braun, G. S., Ihrler, S. & Schmid, H. Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC Pulm. Med. 9, 22 (2009).
34. Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
35. Lang, H. L. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940-943 (2002). (Pubitemid 35154007)
36. Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J. Exp. Med. 205, 1763-1773 (2008).
37. Banwell, B. et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 6, 773-781 (2007). (Pubitemid 47238663)
38. Opsahl, M. L. & Kennedy, P. G. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 128, 516-527 (2005). (Pubitemid 40380187)
39. Alvarez-Lafuente, R. et al. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult. Scler. 14, 595-601 (2008). (Pubitemid 351954400)
40. Yao, K. et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 3, e2028 (2008).
41. Pachner, A. R. & Steiner, I. Lyme neuroborreliosis: infection, immunity, and inflammation. Lancet Neurol. 6, 544-552 (2007). (Pubitemid 46734772)
42. Bradford, R. D. et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-α inhibitors. Clin. Infect. Dis. 49, 924-927 (2009).
43. van Doorn, P. A., Ruts, L. & Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 7, 939-950 (2008).
44. Shin, I. S., Baer, A. N., Kwon, H. J., Papadopoulos, E. J. & Siegel, J. N. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor α antagonist therapy. Arthritis Rheum. 54, 1429-1434 (2006).